(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual revenue growth rate of -18.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
4d Molecular Therapeutics's revenue in 2026 is $92,008,000.On average, 13 Wall Street analysts forecast FDMT's revenue for 2026 to be $730,107,493, with the lowest FDMT revenue forecast at $368,147,422, and the highest FDMT revenue forecast at $1,305,144,485. On average, 12 Wall Street analysts forecast FDMT's revenue for 2027 to be $1,026,824,150, with the lowest FDMT revenue forecast at $0, and the highest FDMT revenue forecast at $2,529,079,980.
In 2028, FDMT is forecast to generate $3,091,189,827 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,707,831,881.